Amicus Therapeutics Reports Strong 2025 Financials and Key M&A Progress Towards BioMarin Acquisition

summarizeSummary

Amicus Therapeutics announced strong full-year 2025 financial results, including 17% revenue growth, and provided a positive update on its pending acquisition by BioMarin, with early termination of the HSR waiting period.

check_boxKey Events

• Reports Strong Full-Year 2025 Financial Results

  Amicus Therapeutics announced total revenues of $634.2 million for 2025, representing 17% year-over-year growth at constant exchange rates, with Galafold sales at $521.7 million and Pombiliti + Opfolda sales at $112.5 million.

• Improves Profitability and Cash Position

  The company reported a GAAP net loss of $27.1 million for 2025, a significant improvement from $56.1 million in 2024, and increased its cash, cash equivalents, and marketable securities to $293.5 million.

• Receives Early HSR Act Termination for BioMarin Acquisition

  The U.S. Federal Trade Commission granted early termination of the waiting period under the HSR Act, moving the proposed $4.8 billion all-cash acquisition by BioMarin Pharmaceutical Inc. closer to its expected Q2 2026 close. This follows the definitive proxy statement filed on February 2, 2026.

auto_awesomeAnalysis

This filing provides the final full-year 2025 financial results, confirming robust revenue growth and an improved cash position, which supports the company's value ahead of its acquisition. Crucially, it also announces the early termination of the HSR waiting period, a significant step that de-risks the regulatory approval process for the proposed $4.8 billion all-cash acquisition by BioMarin. This positive news comes as the stock trades near its 52-week high, reflecting the market's anticipation of the acquisition's completion. Investors should view this as a positive signal for the timely completion of the merger.